ArticleJournal of translational medicine2025
Quercetin promotes angiogenesis and protects the blood-spinal cord barrier structure after spinal cord injury by targeting the PI3K/Akt signaling pathway.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Engineering functional vasculatures to reconstruct sympathetic-parasympathetic circuits for bladder function after spinal cord injury.Bioactive materials · 2027Article
- Article
- Article
- Innovative synergy of bone xenograft and quercetin in the alveolar bone socket: Histological and immunohistochemical assessment of healing.Regenerative therapy · 2026Article
- The multi-target protective effects of quercetin in cerebrovascular diseases: a dietary strategy for endothelial repair and neuroprotection.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundRevascularization and reconstruction of the blood-spinal cord barrier (BSCB) following spinal cord injury (SCI) play crucial roles in supplying essential nutrients and fostering a supportive microenvironment for neural network reconstruction. Thus, facilitating vascular regeneration and maintaining BSCB integrity are key therapeutic targets for functional recovery post-SCI.
methodsIschemia-induced pathological alterations in spinal cord microvascular endothelial cells were modeled in vitro using oxygen-glucose deprivation/reperfusion (OGD/R)-exposed bEnd.3 cells to assess whether QCT protects endothelial cells and enhances their angiogenic capacity. Subsequently, motor function, histopathological morphology, vascular density, and BSCB integrity were evaluated in rats with SCI to examine the therapeutic efficacy of QCT. A network pharmacology approach was employed to predict the potential pharmacological mechanisms of QCT in the treatment of SCI, followed by experimental validation.
resultsQCT enhanced survival, tube formation, and migration of bEnd.3 cells following OGD/R exposure in vitro. In the rat SCI model, QCT demonstrated beneficial effects on vascular regeneration and BSCB integrity, contributing to improved functional recovery. The PI3K/Akt signaling pathway was investigated to elucidate the underlying molecular mechanisms.
conclusionsThese findings suggest that QCT can promote the regeneration of blood vessels in the injured spinal cord and protect the structure of the BSCB by activating the PI3K/Akt signaling pathway, thereby enhancing the neurological function of rats following SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.